U.S. markets open in 4 hours 51 minutes

Shattuck Labs, Inc. (STTK)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
32.48-3.68 (-10.18%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close36.16
Open36.36
Bid0.00 x 800
Ask0.00 x 1400
Day's Range32.14 - 38.94
52 Week Range17.51 - 39.03
Volume287,888
Avg. Volume314,240
Market Cap1.356B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est35.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Shattuck Labs to Present Virtually at Evercore ISI 3rd Annual HealthCONx Conference
      GlobeNewswire

      Shattuck Labs to Present Virtually at Evercore ISI 3rd Annual HealthCONx Conference

      AUSTIN, TX and DURHAM, NC, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in the Evercore ISI 3rd Annual HealthCONx conference being held December 1-3, 2020. Conference Presentation Details Conference: Evercore ISI 3rd Annual HealthCONx Format: Fireside chat with Umer Raffat Presenters: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer and Andrew Neill, Shattuck’s Vice President of Finance and Corporate Strategy Date: December 2, 2020 Time: 1:00 p.m. EST Webcast Link: Available HereThe live webcast of the fireside chat will be available on the Events & Presentations section of the Company’s website. A replay of the webcast will be archived for up to 90 days following the presentation dates.About Shattuck Labs, Inc. Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.Investor Contact: Conor Richardson Director of Finance Shattuck Labs, Inc. InvestorRelations@shattucklabs.comMedia Contact: Stephanie Ascher Managing Director Stern Investor Relations, Inc. Stephanie.ascher@sternir.com

    • Shattuck Labs Reports Third Quarter 2020 Financial Results and Recent Business Highlights
      GlobeNewswire

      Shattuck Labs Reports Third Quarter 2020 Financial Results and Recent Business Highlights

      – Initiated Phase 1 clinical trial for lead wholly owned CD47 checkpoint inhibitor, SL-172154 (SIRPα-Fc-CD40L), for the treatment of ovarian cancer – – Completed initial public offering in October 2020 raising approximately $232.3 million in gross proceeds and extending cash runway through 2024 –AUSTIN, TX and DURHAM, NC, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today reported financial results for the third quarter ended September 30, 2020 and provided recent business highlights.“Shattuck has pioneered the development of bi-functional fusion proteins, and it is a testament to our team to be running multiple clinical trials in just four years from our founding,” said Taylor Schreiber, M.D., Ph.D., and Chief Executive Officer of Shattuck. “This has been a transformative year for Shattuck, and our additional clinical trials and support from a base of world-class investors was enabled by the clinical progress we have made to date. Shattuck now has the balance sheet and vast pipeline to support years of continued growth and execution, to aggressively develop SL-172154 as a differentiated asset in the CD47 field and to continue delivering on our partnership with Takeda Pharmaceuticals on SL-279252.”Recent Business Highlights * Initiated Enrollment of Phase 1 Clinical Trial of SL-172154: In August 2020, Shattuck announced the initiation of a Phase 1 clinical trial for its lead wholly owned asset SL-172154, the second clinical program to advance from its proprietary Agonist Redirected Checkpoint (ARC) platform. SL-172154 is a bi-functional fusion protein that simultaneously blocks the CD47/SIRPα checkpoint and activates the tumor necrosis factor (TNF) costimulatory receptor CD40. The Phase 1 trial will initially evaluate the safety, tolerability, and anti-tumor effects of SL-172154 in patients with ovarian cancer. Initial Phase 1 dose escalation data from the trial are expected in the second half of 2021. * Continued Enrollment of Phase 1 Clinical Trial of SL-279252: The Company is continuing to enroll patients in its Phase 1 clinical trial evaluating SL-279252, a bi-functional fusion protein that simultaneously inhibits the PD-1/PD-L1 interaction and stimulates the OX40 receptor pathway in immune cells. The Phase 1 trial is an open label, multi-center, dose escalation, and dose expansion study to evaluate the safety, tolerability, PK, anti-tumor activity, and pharmacodynamics effects of SL-279252 in patients with advanced solid tumors or lymphomas. SL-279252 is currently being developed in collaboration with Takeda Pharmaceuticals. Phase 1 dose escalation data from the trial are expected in the second half of 2021. * Completed Initial Public Offering (IPO): In October 2020, Shattuck completed an upsized IPO of common stock at $17.00 per share, raising gross proceeds of approximately $232.3 million, before deducting underwriting discounts, commissions, and estimated offering costs. * Presented at TIGIT Therapies Summit: In October 2020, Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck, presented at the TIGIT Therapies Summit on exploring the novel method of modulating T cell function using TIGIT inhibition and presenting initial preclinical data of SL-9258 (TIGIT-Fc-LIGHT), a bi-functional fusion protein that simultaneously blocks the TIGIT/PVR checkpoint and activates the TNF costimulatory receptor known as LIGHT. * Advanced GADLEN Platform: The Company continues to advance its deep preclinical pipeline, including a second proprietary platform, the Gamma Delta T Cell Engager (GADLEN™) platform. In November 2020, Shattuck presented an update on the progress of the GADLEN platform at the Society for Immunotherapy of Cancer (SITC) Meeting. * Appointed New Director: In July 2020, Helen M. Boudreau was appointed to Shattuck’s Board of Directors and currently serves as the Audit Committee chair and a member of the Compensation Committee. Ms. Boudreau brings over 30 years of corporate and financial expertise in the life sciences and healthcare industries. Third Quarter 2020 Financial Results * Cash and Investments: As of September 30, 2020, cash, cash equivalents, and short-term investments were $134.9 million, which does not include total net proceeds of approximately $213.5 million from the Company’s IPO completed in October 2020. * Research and Development (R&D) Expenses: R&D expenses were $11.8 million for the third quarter of 2020, as compared to $7.9 million for the third quarter of 2019. * General and Administrative (G&A) Expenses: G&A expenses were $2.5 million for the third quarter of 2020, as compared to $1.4 million for the third quarter of 2019. * Net Loss: Net loss was $11.8 million for the third quarter of 2020, or $1.54 per basic and diluted share, as compared to a net loss of $7.3 million for the third quarter of 2019, or $0.96 per basic and diluted share. Financial GuidanceThe Company believes its cash, cash equivalents, and short-term investments, together with the net proceeds of its successful IPO on The Nasdaq Global Select Market will be sufficient to fund its anticipated operations through 2024, which is beyond results from its Phase 1 clinical trials of SL-172154 and SL-279252. This cash runway guidance is based on the Company’s current operational plans and excludes any additional funding that may be received or business development activities that may be undertaken.About Shattuck Labs, Inc.Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.Forward-Looking StatementsCertain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, our expectations regarding plans for our preclinical studies, clinical trials and research and development programs, the anticipated timing of the results from those studies and trials, and expectations regarding the time period over which our capital resources will be sufficient to fund our anticipated operations. Words such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “develop,” “plan” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While we believe these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in our filings with the U.S. Securities and Exchange Commission (the “SEC”)), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include: the recent and ongoing COVID-19 pandemic and associated shelter-in-place orders; expectations regarding the initiation, progress, and expected results of our preclinical studies, clinical trials and research and development programs; expectations regarding the timing, completion and outcome of our Phase 1 clinical trials; the unpredictable relationship between preclinical study results and clinical study results; the timing or likelihood of regulatory filings and approvals; liquidity and capital resources; and other risks and uncertainties identified in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, to be filed on November 13, 2020 with the SEC. We claim the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We expressly disclaim any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.Investor Contact: Conor Richardson Director of Finance Shattuck Labs, Inc. InvestorRelations@shattucklabs.comMedia Contact: Stephanie Ascher Managing Director Stern Investor Relations, Inc. Stephanie.Ascher@sternir.comFinancialsShattuck Labs, Inc.     Condensed Balance Sheets     (Unaudited)     (In thousands, except share and per share amounts)               September 30, 2020 December 31, 2019 Assets    Current assets:     Cash and cash equivalents$128,600  $7,013   Short-term investments 6,339   32,074   Prepaid expenses and other current assets 7,315   3,355    Total current assets 142,254   42,442  Property and equipment, net 2,515   2,437  Other assets 89   90    Total assets$ 144,858  $ 44,969         Liabilities, redeemable convertible preferred stock and stockholder' deficit    Current liabilities:     Accounts payable$1,350  $3,051   Accrued expenses 6,518   4,039   Deferred revenue – related party 8,613   12,894    Total current liabilities 16,481   19,984  Deferred revenue – related party net of current portion 19,722   9,571  Deferred rent 911   898    Total liabilities 37,114   30,453         Series A redeemable convertible preferred stock 49,064   49,064  Series B redeemable convertible preferred stock 34,427   -  Series B-1 redeemable convertible preferred stock 82,613   -         Stockholders' deficit:     Common stock 1   1   Additional paid-in capital 1,730   887   Accumulated other comprehensive income (loss) (10)  54   Accumulated deficit (60,081)  (35,490)   Total stockholders' deficit (58,360)  (34,548)   Total liabilities, redeemable convertible preferred stock and stockholders' deficit$ 144,858  $ 44,969         Shattuck Labs, Inc.      Condensed Statements of Operations      (Unaudited)      (In thousands, except share and per share amounts)                    Three Months Ended September 30, Nine Months Ended September 30,     2020   2019   2020   2019  Collaboration revenue – related party$2,435  $1,784  $8,592  $7,066  Operating expenses:         Research and development 11,804   7,945   27,696   20,447   General and administrative 2,470   1,366   5,816   4,062    Expense from operations 14,274   9,311   33,512   24,509  Loss from operations (11,839)  (7,527)  (24,920)  (17,443)            Other income (expense):         Interest income 86   279   474   902   Other (76)  (31)  (145)  (72)   Total other income 10   248   329   830  Net loss$(11,829) $(7,279) $(24,591) $(16,613) Unrealized gain (loss) on short-term investments (28)  10   (64)  119  Comprehensive loss$(11,857) $(7,269) $(24,655) $(16,494) Net loss per share – basic and diluted$(1.54) $(0.96) $(3.21) $(2.20) Weighted-average ordinary shares used in computing net loss per share attributable to ordinary shareholders—basic and diluted 7,700,371   7,572,746   7,656,077   7,543,831

    • Shattuck Labs Announces Preclinical Proof of Concept Study on Gamma Delta T Cell Engager, GADLEN™, Platform at SITC 2020
      GlobeNewswire

      Shattuck Labs Announces Preclinical Proof of Concept Study on Gamma Delta T Cell Engager, GADLEN™, Platform at SITC 2020

      AUSTIN, TX and DURHAM, NC, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the presentation of preclinical data from its Gamma Delta T Cell Engager, or GADLEN™, platform. The presentation, titled “In vivo expansion of gamma delta T cells by a CD19-targeted butyrophilin heterodimer leads to elimination of peripheral B cells”, will be presented by Suresh de Silva, Ph.D., VP of Product Development at Shattuck, at the Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting, which is being held virtually November 9-14, 2020. The GADLEN platform is a novel class of bi-functional fusion proteins that are T cell engager molecules targeting gamma delta T cells to kill tumor cells expressing specific tumor antigens. The presentation demonstrates that a mouse butyrophilin heterodimer can activate mouse gamma delta T cells in vitro and in vivo to target the killing of lymphoma cells expressing the CD19 antigen. Additionally, the human heterodimeric fusion protein BTN2A1/3A1-Fc-CD19scFv, has also demonstrated its ability to bind both the V9V2 on gamma delta T cells and CD19 on lymphoma cells.“In vivo manipulation of gamma delta T cells holds great promise for treating cancers that are resistant or refractory to immune checkpoint blockade, however technical challenges have hindered this therapeutic goal until recently,” said Taylor Schreiber, M.D., Ph.D., and Chief Executive Officer of Shattuck. “These data indicate that dual-sided fusion proteins comprising butyrophilin heterodimers are well-suited to engage gamma delta T cells in vivo, stimulate those cells to proliferate and specifically kill CD19 positive tumor cells. While CD19 is a useful model antigen for feasibility, we believe these data pave the way to develop GADLEN compounds for a range of tumors and tumor antigens.”The poster presentation will be available under the Events & Presentations section of the Company’s website.About Shattuck Labs, Inc. Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.comForward Looking Statements Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, our expectations regarding results from our preclinical studies and our expectations regarding our GADLEN platform, its promise for treating cancer and autoimmune diseases and its potential to address checkpoint refractory patients and other areas of high unmet needs. Words such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “promises,” “estimate,” “predict,” “potential,” “develop,” “plan” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While we believe these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in our filings with the U.S. Securities and Exchange Commission (the “SEC”)), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include: expectations regarding the initiation, progress, and expected results of our preclinical studies, clinical trials and research and development programs; the unpredictable relationship between preclinical study results and clinical study results; and other risks and uncertainties identified in our Registration Statement on Form S-1 (File No. 333-248918), as amended, filed with the U.S. Securities and Exchange Commission. We claim the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We expressly disclaim any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.Investor Contact: Conor Richardson Director of Finance Shattuck Labs, Inc. InvestorRelations@shattucklabs.comMedia Contact: Stephanie Ascher Managing Director Stern Investor Relations, Inc. Stephanie.ascher@sternir.com